Crizanlizumab
- Product Name
- Crizanlizumab
- CAS No.
- 1690318-25-2
- Chemical Name
- Crizanlizumab
- Synonyms
- Crizanlizumab;ADAKVEO|||SEG-101;Research Grade Crizanlizumab;Crizanlizumab (anti-P-Selectin);Research Grade Crizanlizumab (DHD15101)
- CBNumber
- CB88081012
- Formula Weight
- 0
- MOL File
- Mol file
Crizanlizumab Property
- form
- Liquid
- color
- Colorless to light yellow
Crizanlizumab Chemical Properties,Usage,Production
Uses
Crizanlizumab is an anti-P-selectin monoclonal antibody. Crizanlizumab binds to P-selectin and blocks its interaction with P-selectin glycoprotein ligand 1 (PSGL-1). Crizanlizumab prevents vaso-occlusive crises (VOCs) and can be used for research of sickle cell disease[1][2][3].
in vivo
Crizanlizumab (1 or 6 mg/kg, i.p., 3 days a week for 5 months) improving sickle cell retinopathy in four weeks old male HbSS (sickle cell disease) mice[3].
References
[1] Hannah A. Blair, et al. Crizanlizumab: First Approval. Drugs. 80, 79-84 (2020).
[2] Ataga KI, et al. Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med. 2017 Feb 2;376(5):429-439. DOI:10.1056/NEJMoa1611770
[3] Ravirajsinh Jadeja, et al. Therapeutic potential of Crizanlizumab (anti-P-selectin) in improving sickle cell retinopathy in mice. Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4747.